Alexion Pharmaceuticals, Inc. (ALXN) SVP Heidi L. Wagner Sells 120 Shares
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 120 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $140.00, for a total value of $16,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up 0.32% during mid-day trading on Wednesday, reaching $141.93. The company’s stock had a trading volume of 1,283,999 shares. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a 50 day moving average of $140.86 and a 200-day moving average of $126.01. The firm has a market capitalization of $31.68 billion, a P/E ratio of 61.55 and a beta of 1.39.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. During the same period in the prior year, the company posted $1.13 EPS. The company’s revenue was up 21.1% compared to the same quarter last year. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current year.
A number of equities research analysts have weighed in on ALXN shares. Jefferies Group LLC set a $120.00 price objective on Alexion Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, June 8th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $142.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, June 9th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Morgan Stanley restated an “overweight” rating and set a $138.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 14th. Finally, UBS AG restated a “buy” rating and set a $108.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 14th. Six research analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average target price of $157.21.
Hedge funds have recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America grew its stake in shares of Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 6 shares during the period. Meeder Asset Management Inc. bought a new stake in Alexion Pharmaceuticals during the 1st quarter worth approximately $111,000. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals during the 2nd quarter worth approximately $111,000. Huntington National Bank grew its position in Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares during the last quarter. Finally, Penserra Capital Management LLC grew its position in Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares during the last quarter. Institutional investors own 94.25% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.